RS-0826

RS-0826 is a theranostic radiopharmaceutical candidate developed by RS Research (RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret). It is designed to target the **Prostate-Specific Membrane Antigen (PSMA)**, a cell-surface protein that is significantly overexpressed in prostate cancer cells and the neovasculature of various other solid tumors. As a theranostic pair, RS-0826 can be labeled with different radioisotopes for dual purposes: **Gallium-68 (^68Ga)** is utilized for diagnostic positron emission tomography (PET) imaging to localize and stage tumors, while **Lutetium-177 (^177Lu)** is used for targeted radionuclide therapy to deliver localized beta-particle radiation directly to the tumor site. This approach aims to maximize therapeutic efficacy while minimizing off-target toxicity to healthy tissues. RS-0826 is part of RS Research's broader portfolio of targeted oncology therapies and is currently in the preclinical stage of development.